Stifel analyst Dae Gon Ha upgraded Editas Medicine (EDIT) to Buy from Hold with a price target of $17, up from $9. The analyst thinks EDIT-301’s progress in sickle cell disease has received minimal credit from investors. With a year-end 2023 goal to dose 20 patients, in addition to regulatory insights expected from Crispr Therapeutics’ (CRSP) exa-cel, EDIT-301 “deserves a fresh look,” the analyst tells investors in a research note. The firm sees a “disconnect” between Editas’ and Crispr’s valuations, which it finds difficult to justify.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EDIT:
- Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
- Editas Medicine appoints Caren Deardorf as chief commercial, strategy officer
- Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
- Editas Medicine Announces Upcoming Investor Events
- Medicenna Therapeutics appoints Jeff Caravella as CFO